Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study

[PR Newswire] – INDIANAPOLIS, June 17, 2015 /PRNewswire/ — Eli Lilly and Company (LLY) announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint . . . → Read More: Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study Similar Articles: Company Update (NYSE:LLY): Lilly Announces Webcast to Discuss Ixekizumab Phase III Data Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly Declares Second-Quarter 2015 Dividend Market Update (NYSE:LLY): Lilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement